secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2026-05-20T20:01:49+00:00
Accession:  0001193125-26-232524
Event type: other
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inovio stockholders elect eight directors, approve omnibus plan at annual meeting
--------------------------------------------------------------------------------

- All eight director nominees elected; votes for ranged from 22.3M to 22.7M, with 17.1M broker non-votes.
- Ratification of Ernst & Young as auditor for 2026 approved: 39.3M for, 1.2M against, 143k abstain.
- Non-binding advisory vote on NEO compensation passed with 21.5M for, 1.6M against, 471k abstain.
- Amendment and restatement of 2023 Omnibus Incentive Plan approved with 21.6M for, 1.5M against.
- Board adopted bylaw amendment establishing Lead Independent Director role and clarifying Chairman duties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312526232524/0001193125-26-232524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312526232524/d138309d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-232524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer